Is apomorphine neurotoxic?

Biogenic Amines

Volumn 16, Issue 4-5, 2001, Pages 463-471

  El Bacha, R D S ^a   Daval, J L ^a   Netter, P ^a   Minn, A ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Apomorphine; Autoxidation; Catechols; Neurotoxicity; Oxidative stress; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; CATECHOL; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROMELANIN; QUINOLONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REAGENT; THIOL;

ARTICLE; AUTOOXIDATION; CELL CULTURE; CELL DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENCY; IN VITRO STUDY; MODEL; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT; TIME;

EID: 0035156919     PISSN: 01688561     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Levodopa: Is toxicity a myth?
2. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease
3. Dopamine neurotoxicity: Inhibition of mitochondrial respiration
4. Biochemical and toxicological properties of the oxidation products of catecholamines
5. Extracellular toxicity of 6-hydroxydopamine on PC12 cells
6. Apomorphine for motor fluctuations and freezing in Parkinson's disease
7. A simple method for evaluation of superoxide radical production in neural cells under various culture conditions: Application to hypoxia
8. Astrocytes protect neurons from hydrogen peroxide toxicity
9. Intranasal apomorphine rescue therapy for parkinsonian "off" periods
10. Toxic effects of apomorphine on rat C6 glial cells, and protection with antioxidants
11. Glucuronidation of apomorphine
12. Mechanisms of apomorphine neurotoxicity towards rat glioma C6 cells: Protection by bovine serumalbumin and formation of apomorphine-protein conjugates
13. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: An in vivo microdialysis study
14. Enzyme-mediated superoxide formation initiated by exogenous molecules in rat brain
15. NADPH: Cytochrome P-450(c) reductase: Biochemical characterization in rat brain and cultured neurones and evolution of activity during development
16. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease
17. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study
18. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
19. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease
20. Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration?
21. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
22. Biochemical pathophysiology of Parkinson's disease
23. Oxidative mechanisms in nigral cell death in Parkinson's disease
24. Levodopa neurotoxicity: Experimental studies versus clinical relevance
25. Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells
26. Protein measurement with the Folin phenol reagent
27. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease
28. Redox cycling of radical anion metabolites of toxic chemicals and drugs and the Marcus theory of electron transfer
29. Glia protect midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms
30. Apomorphine in patients with Parkinson's disease
31. Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration
32. A mathematical model of pathogenesis in idiopathic parkinsonism
33. The early treatment of Parkinson's disease: Levodopa, dopamine agonists or both
34. Thiols can either enhance or suppress DNA damage induction by catecholestrogens
35. COMT inhibitors and liver toxicity
36. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist, apomorphine